Data-Driven Decision Support in Obesity Management Commission: enabling more equitable and personalized obesity care
Paul W. Franks / nature - Nature Medicine, Published online: 12 May 2026; doi:10.1038/s41591-026-04363-0Announced in this Comment and in collaboration with Nature Medicine is the convening of the Data-Driven Decision Support in Obesity Management Commission, to promote adequate sc…
AI Summary: A phase 1/2 study of CRISPR‑Cas9 CD33‑deleted allogeneic hematopoietic cell transplantation followed by gemtuzumab ozogamicin maintenance reports encouraging early signals in AML. The gene‑editing approach aims to protect donor cells from CD33‑targeted therapy, potentially enabling safer post‑transplant maintenance and offering a novel strategy to marry cellular engineering with targeted antibody therapy.
- CD33‑targeted transplant and post‑transplant maintenance (4)
- Safety and ethical scrutiny of gene editing and gene therapy (3)
- Scaling cell therapy: accreditation and expanding CAR indications (3)
- All Other Stories
CD33‑targeted transplant and post‑transplant maintenance
Safety and ethical scrutiny of gene editing and gene therapy
Scaling cell therapy: accreditation and expanding CAR indications
All Other Stories
When should you get a mammogram? Conflicting advice makes it hard to know
medicalxpress - Deciding when to get routine mammograms is confusing. Some health groups recommend women begin at age 40 or 45 while another recently opted for age 50. They also differ on whether yearly or every other year is best.
AI Summary: Conflicting guidance about when to start and how often to perform mammography continues to confuse patients and clinicians, complicating shared decision‑making. Experts urge individualized risk assessment and clearer communication of benefits and harms to reduce both undertreatment and unnecessary anxiety, because apparently screening schedules enjoy being controversial.
- Patient confusion over mammogram timing (2)
- Risk-based screening: AI and trials (3)
- USPSTF political shake-up threatens screening guidance (4)
- All Other Stories
Patient confusion over mammogram timing
Risk-based screening: AI and trials
USPSTF political shake-up threatens screening guidance
All Other Stories
Omid Veiseh: First-in-Human Clinical Trial of IL-2 Cytokine Factories in Refractory Ovarian Cancer
oncodaily - Omid Veiseh, Professor and CPRIT Scholar in Cancer Research at Rice University and Co-Founder and Managing Partner of RBL LLC, shared a post on LinkedIn: “Excited to publish the results […]
AI Summary: A first‑in‑human trial of implantable IL‑2 “cytokine factories” in refractory ovarian cancer reported encouraging early safety and biological activity, offering a localized immune‑stimulation strategy that may boost tumor responses while avoiding systemic toxicity. Investigators described the device‑based platform as a potential option for patients with limited alternatives, pending larger efficacy studies.
BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta
Ayisha Sharma / endpoints - BeOne Medicines has clinched US accelerated approval for its drug sonrotoclax in a rare but aggressive form of blood cancer, where AbbVie and Genentech’s Venclexta is used off-label. The FDA greenlit ...
AI Summary: BeOne Medicines secured FDA approval for a next-generation BCL2 inhibitor, positioning the drug as a direct challenge to AbbVie/Roche’s Venclexta franchise. The move reshuffles competitive dynamics in hematology, potentially offering clinicians an alternative and setting the stage for market share battles and payer negotiations. Expect aggressive positioning and head-to-head data requests.
Positive VOLGA Phase III Results for Imfinzi Plus Neoadjuvant EV in MIBC
oncodaily - On May 14, 2026, AstraZeneca announced positive high-level results from a planned interim analysis of the Phase III VOLGA trial, evaluating perioperative Imfinzi with or without Imjudo in combination with […]
AI Summary: Phase III VOLGA trial results reveal that combining durvalumab (Imfinzi) with neoadjuvant enfortumab vedotin improved survival outcomes in muscle‑invasive bladder cancer. Investigators and industry voices highlight potential practice-changing implications for perioperative therapy, while stakeholders weigh regulatory filings and integration into treatment guidelines. Clinicians will want full datasets and toxicity details.
- Clinician reactions, biology and resistance concerns (4)
- Global GU oncology meetings and community coverage (3)
- VOLGA Phase III readout and regulatory landscape (3)
- All Other Stories